Australian scientists said Monday they had developed a drug which holds promise to spell an end to a life-threatening condition caused by diabetes, heart disease and other illnesses.
Scientists from the University of Melbourne and the city's St Vincent's Hospital said the drug had been shown in animal trials to prevent fibrosis, the build-up of irreversible scarring on internal organs.
Diabetes and Exercise
Regular exercise especially in type II diabetes not only helps reduce the sugar but also reduces the demand for medication by 20% and helps you stay healthy.
Advertisement
There are currently no treatments on the market for fibrosis and the new drug, called FT-11, could be as important a discovery as blood pressure drugs if effective, said Professor Darren Kelly of the University of Melbourne.
"It would be an enormous blockbuster drug with an initial market of around 2.0 billion dollars," he said.
Kelly said while the drug would not prevent diabetes -- a chronic illness in which the body fails to produce enough of the hormone insulin to process sugar -- it could prevent complications such as kidney or heart disease.
![Angioplasty - Animation]( "Angioplasty - Animation")
Arteries supplying the heart is sometimes blocked by plaque leading to heart attack.Angioplasty is a method by which a part of the blocked artery is expanded to place a stent.Once this is done normal blood flow resumes and the heart regains its normal function.
"We are hoping to delay or prevent those complications which would basically keep those patients off dialysis -- which would have a huge benefit for their lifestyle," Kelly told AFP.
The drug, expected to be tested in clinical trials within 12 months, could be used to prevent diabetic kidney disease, heart disease and potentially other health problems such as liver and lung fibrosis, he said.
Speaking to the Australian Broadcasting Corporation, Kelly said about 45 percent of diseases in the developed world could be associated with some sort of pathological fibrosis.
"We know at the moment in rat studies that our compound inhibited the development of fibrosis, and the interesting thing in the future would be to see whether we can actually reverse fibrosis," he said.
Source: AFP
THK/L
Kelly said while the drug would not prevent diabetes -- a chronic illness in which the body fails to produce enough of the hormone insulin to process sugar -- it could prevent complications such as kidney or heart disease.
Angioplasty - Animation
Arteries supplying the heart is sometimes blocked by plaque leading to heart attack.Angioplasty is a method by which a part of the blocked artery is expanded to place a stent.Once this is done normal blood flow resumes and the heart regains its normal function.
Advertisement
"We are hoping to delay or prevent those complications which would basically keep those patients off dialysis -- which would have a huge benefit for their lifestyle," Kelly told AFP.
The drug, expected to be tested in clinical trials within 12 months, could be used to prevent diabetic kidney disease, heart disease and potentially other health problems such as liver and lung fibrosis, he said.
Speaking to the Australian Broadcasting Corporation, Kelly said about 45 percent of diseases in the developed world could be associated with some sort of pathological fibrosis.
"We know at the moment in rat studies that our compound inhibited the development of fibrosis, and the interesting thing in the future would be to see whether we can actually reverse fibrosis," he said.
Source: AFP
THK/L
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Diabetes News
Physical activity or exercise in the morning and afternoon reduces type 2 diabetes risk, whereas evening exercise has no such association.
Late sleepers and late risers may both have a higher risk of developing diabetes.
Semaglutide, the anti-diabetic drug operating by stimulating insulin secretion, might have the potential to supplant the need for mealtime insulin injections.
The gut bacteria known as Lachnospiraceae might have the ability to boost insulin sensitivity, potentially providing a protective barrier against diabetes.
Type 2 diabetes-led cardiovascular risk needs mandatory interdisciplinary, patient-centered care to reduce morbidity and mortality.
